Shoulder operation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:28:47 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Shoulder operation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Dexmedetomidine and Ropivacaine for Pain Relief in Shoulder Surgery Patients https://clinicaltrials.eu/trial/study-on-dexmedetomidine-and-ropivacaine-for-pain-relief-in-shoulder-surgery-patients/ Wed, 29 Apr 2026 14:23:33 +0000 https://clinicaltrials.eu/trial/study-on-dexmedetomidine-and-ropivacaine-for-pain-relief-in-shoulder-surgery-patients/ This clinical trial is focused on patients who are scheduled for shoulder surgeries. The study is investigating the use of different doses of perineural dexmedetomidine as an additional treatment to ropivacaine for a procedure called an interscalene plexus block. This block is a type of anesthesia used to numb the shoulder area during surgery. Additionally, patients will receive dexamethasone intravenously, which means it will be administered directly into a vein.

The purpose of the study is to determine how effective different doses of dexmedetomidine are in prolonging the pain relief provided by the interscalene plexus block. The study will compare the duration of pain relief, the length of time the area remains numb, and the time it takes for muscle movement to return. It will also monitor any side effects such as nausea, vomiting, low blood pressure, or slow heart rate during the first 48 hours after surgery. The study will also track the amount of pain medication needed after surgery and the time it takes for patients to recover from anesthesia.

Participants in the study will be randomly assigned to receive different doses of dexmedetomidine along with ropivacaine and dexamethasone, or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are unbiased. The study is expected to continue until June 2025.

]]>